HOME > TOP STORIES
TOP STORIES
-
REGULATORY Off-Year Price Revisions Should Either Be Abolished or Revisited: LDP Lawmakers
May 21, 2024
-
REGULATORY Bridion Sees Rare May Generic Entry for New Dosage Form in Japan
May 21, 2024
-
REGULATORY Japan’s 1st Stelara Biosimilar Gets Listing, New Kit Products Too
May 21, 2024
-
BUSINESS Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
-
BUSINESS Amylyx Pulls Out from Japan after ALS Trial Flop
May 20, 2024
-
REGULATORY Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
-
REGULATORY First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
-
REGULATORY Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
-
REGULATORY Alexion Takes Hit from 1st Market Expansion Re-Pricing of Ultomiris, Soliris
May 16, 2024
-
REGULATORY BMS’s Sotyktu to Get 8.6% Price Cut in August after Cost-Effectiveness Assessment
May 16, 2024
-
REGULATORY Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
May 15, 2024
-
BUSINESS As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
-
BUSINESS Teva to Let Go of Japan Generic Business in 2025 but Denies Full Exit
May 15, 2024
-
ACADEMIA Researchers Crafting Japan’s 1st Guidelines for ALS Trials, Eye FY2026 Completion
May 14, 2024
-
BUSINESS Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
-
BUSINESS Moderna Set to Develop Cancer Vaccines, Rare Disease Therapies in Japan: New Local Chief
May 10, 2024
-
BUSINESS Lilly Japan Nets 10% Sales Rise in 2023, Eyes No. 1 Growth for Protected Medicines
May 9, 2024
-
BUSINESS Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
May 9, 2024
-
ACADEMIA Japan to Forge National Registry for Leqembi, Test Genes to Predict Side Effects
May 8, 2024
-
REGULATORY New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
